Ozmosi | Aldesleukin Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Aldesleukin

Alternative Names: aldesleukin, proleukin, recombinant human interleukin-2, ril-2, ilt-101, ilt101
Clinical Status: Inactive
Latest Update: 2026-03-09
Latest Update Note: Clinical Trial Update

Product Description

Aldesleukin is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the kidney) that has spread to other parts of your body. Aldesleukin is also used to treat melanoma (a type of skin cancer) that has spread to other parts of your body. Aldesleukin is in a class of drugs known as cytokines. It is a man-made version of a naturally occurring protein that stimulates the body to produce other chemicals which increase the body's ability to fight cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a692009.html)

Mechanisms of Action: IL2 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous, Subcutaneous

FDA Designation: *

Approval Status: Approved

Approved Countries: Austria | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | France | Germany | Greece | Hungary | Ireland | Italy | Korea | Netherlands | New Zealand | Peru | Portugal | Slovenia | Spain | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Chiron
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aldesleukin

Countries in Clinic: China, France, Germany, Hong Kong, Israel, Korea, New Zealand, United Kingdom, United States

Active Clinical Trial Count: 19

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Adenocarcinoma|Alzheimer Disease|Anal Cancer|Anus Cancer|Bladder Cancer|Carcinoma, Adenosquamous|Carcinoma, Merkel Cell|Cervical Cancer|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Diabetes Complications|Digestive System Cancer|Esophageal Cancer|Gallbladder Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Melanoma|Neuroblastoma|Non-Small-Cell Lung Cancer|Oropharyngeal Cancer|Ovarian Cancer|Pancreatic Cancer|Penile Cancer|Prostate Cancer|Renal Cell Carcinoma|Skin Cancer|Soft Tissue Cancer|Squamous Cell Carcinoma|Synovial Sarcoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Type 1 Diabetes|Uterine Cancer|Vaginal Cancer|Vulvar Cancer

Phase 1: Breast Cancer|Hepatitis B|Lung Cancer|Mesothelioma|Oncology Solid Tumor Unspecified|Pleural Effusion, Malignant

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT07192900

(RIOT 4A)

P1

Recruiting

Mesothelioma|Pleural Effusion, Malignant

2032-12-01

12%

2026-01-16

NCT05483491

Pro2022002198

P1

Recruiting

Lung Cancer|Cervical Cancer|Uterine Cancer|Breast Cancer|Gastrointestinal Cancer

2026-09-01

50%

2024-07-13

NCT04862767

ATB-301-001

P1

Completed

Oncology Solid Tumor Unspecified

2023-08-21

2%

2024-02-01

NCT05153070

DF-IL2-REP

P2

Recruiting

Type 1 Diabetes

2026-04-21

12%

2024-11-22

NCT05468073

IL-2-AD

P2

Recruiting

Alzheimer Disease

2025-09-01

2024-06-28

Primary Endpoints

NCT04426669

2019LS002

P2

Completed

Colorectal Cancer|Digestive System Cancer|Esophageal Cancer|Pancreatic Cancer|Gastrointestinal Cancer|Gallbladder Cancer

2025-05-28

12%

2026-02-24

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

2012-001786-32

IL2HD

P2

Completed

Melanoma|Renal Cell Carcinoma

2024-12-31

2025-05-06

Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT03782636

ITAD

P2

Active, not recruiting

Type 1 Diabetes|Diabetes Complications

2023-02-16

2025-10-04

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT07288073

NCT07288073

P2

Recruiting

Squamous Cell Carcinoma|Carcinoma, Merkel Cell|Cutaneous Squamous Cell Carcinoma|Skin Cancer

2028-09-29

12%

2026-02-14

Primary Endpoints|Start Date

NCT05296564

0752-20-HMO

P2

Recruiting

Non-Small-Cell Lung Cancer|Neuroblastoma|Synovial Sarcoma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Soft Tissue Cancer|Ovarian Cancer|Melanoma|Bladder Cancer

2027-12-30

2023-09-26

Primary Endpoints|Treatments

NCT07255664

ProbeTILity

P2

Recruiting

Prostate Cancer|Colorectal Cancer

2027-04-01

12%

2025-12-11

Primary Endpoints|Start Date|Treatments|Trial Status

NCT05686226

Pro2022002259

P2

Recruiting

Penile Cancer|Vulvar Cancer|Colorectal Cancer|Head and Neck Cancer|Carcinoma, Adenosquamous|Uterine Cancer|Cervical Cancer|Vaginal Cancer|Anus Cancer|Adenocarcinoma|Squamous Cell Carcinoma|Oropharyngeal Cancer|Anal Cancer

2027-01-01

12%

2025-04-01

Primary Completion Date|Primary Endpoints

NCT05639972

Pro2022000437

P2

Recruiting

Anus Cancer|Penile Cancer|Vulvar Cancer|Anal Cancer|Squamous Cell Carcinoma|Carcinoma, Adenosquamous|Cervical Cancer|Uterine Cancer|Vaginal Cancer|Oropharyngeal Cancer|Adenocarcinoma|Head and Neck Cancer

2026-10-01

12%

2025-04-01

Primary Endpoints|Start Date|Treatments|Trial Status

2020-003629-45

Study of LN 145 in patients with Metastatic Non-Small-Cell Lung Cancer

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2026-05-05

12%

2022-03-13

Treatments

ACTRN12618001843246p

2006-7041-83/hah

P1

Not yet recruiting

Hepatitis B

None

CTR20231525

CTR20231525

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

None

2025-04-29

2012-001410-41

ABSIDE

P2

Completed

Melanoma

2024-06-20

2025-05-06

Primary Completion Date|Study Completion Date|Treatments|Trial Status

2020-005068-70

DFIL2-REP

P2

Active, not recruiting

Unknown

2022-12-07

2022-03-13

Treatments

2025-521227-70-00

ProbeTILity

P2

Not yet recruiting

Colorectal Cancer|Prostate Cancer

2029-03-01

12%